Maxim Rossmann

Cambridge Oncometrix Ltd. engages in the development of prostate cancer risk stratification test solutions. Its non-invasive pre-biopsy diagnostic test allows for improved prostate cancer risk assessment in primary and secondary care. The company was founded by Maxim Rossmann, Dmitry Soloviev, Irina Soltamova Solovyev, and Pavel Shashkov and is headquartered in Norwich, the United Kingdom.

Cambridge Oncometrix Ltd. engages in the development of prostate cancer risk stratification test solutions. Its non-invasive pre-biopsy diagnostic test allows for improved prostate cancer risk assessment in primary and secondary care. The company was founded by Maxim Rossmann, Dmitry Soloviev, Irina Soltamova Solovyev, and Pavel Shashkov and is headquartered in Norwich, the United Kingdom.

Cambridge Oncometrix Ltd. engages in the development of prostate cancer risk stratification test solutions. Its non-invasive pre-biopsy diagnostic test allows for improved prostate cancer risk assessment in primary and secondary care. The company was founded by Maxim Rossmann, Dmitry Soloviev, Irina Soltamova Solovyev, and Pavel Shashkov and is headquartered in Norwich, the United Kingdom.

Cambridge Oncometrix Ltd. engages in the development of prostate cancer risk stratification test solutions. Its non-invasive pre-biopsy diagnostic test allows for improved prostate cancer risk assessment in primary and secondary care. The company was founded by Maxim Rossmann, Dmitry Soloviev, Irina Soltamova Solovyev, and Pavel Shashkov and is headquartered in Norwich, the United Kingdom.